Contact Us
Contact Us

Developing next generation therapeutics targeting immune suppression in cancer.

WHO WE ARE

Our team has a proven track record with immunology expertise in cancer and inflammation.
MEET OUR TEAM

WHAT WE DO

We are developing novel drugs targeting a class of immune cells called myeloid cells to directly treat cancer as well as to enhance the benefits of current Immuno Oncology drugs such as checkpoint inhibitors in currently untreatable cancers.
LEARN MORE

THE SCIENCE

Immuno Oncology (IO) is a new area of cancer research which has been successful in treating previously untreatable cancers. IO targets the immune system rather than the cancer directly which potentially allows a single IO drug to be used to treat multiple cancer types with mostly manageable side effects.

READ MORE

NEWSROOM

Our latest company news and scientific findings.

,

|

04/04/2024

ME THERAPEUTICS ANNOUNCES UPCOMING PARTICIPATION IN THE 2024 BLOOM BURTON & CO HEALTH CARE CONFERENCE AND INTERVIEW ON CSE TV

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

04/04/2024

ME THERAPEUTICS ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

03/01/2024

ME THERAPEUTICS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT AND PROVIDES CORPORATE UPDATE

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

01/25/2024

ME THERAPEUTICS HOLDINGS INC. PROVIDES CORPORATE UPDATES

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

12/15/2023

ME THERAPEUTICS HOLDINGS INC. ANNOUCES LISTING ON THE FRANKFURT STOCK EXCHANGE (FSE) AND THE COMPLETION OF ITS REDESIGNED WEBSITE

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....

,

|

12/07/2023

ME THERAPEUTICS HOLDINGS INC. Provides An Overview And Update On Current Research And Development Programs

ME Therapeutics Holdings Inc. (METX:CSE), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of....
View All

Keep up to date by subscribing to our mailing list

ME Therapeutics Inc.

Links

Social

Get In Touch

ME Therapeutics
177 Robson St.
Vancouver, BC,Canada
V6B 0N3

© 2023 ME Therapeutics All Rights Reserved.

METX (CSE)
Q9T (FSE)